Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 15, 2025 /PRNewswire/ -- Fa ...

NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, ...

Core Viewpoint - A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. for allegedly providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant financial losses for investors [1][3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Rocket securities between February 27, 2025, and May 26, 2025, with a deadline of August 11, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Rocket made positive statements while concealing serious risks, including the occurrence of Serious Adverse Events (SAEs) during clinical trials [3]. Clinical Trial Issues - Rocket amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which is claimed to have misled investors about the safety of the treatment [3]. - On May 27, 2025, the FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a SAE, which included death, following the undisclosed protocol amendment [4]. Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in one trading day [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Fortrea Holdings, alleging that the company made false and misleading statements regarding its revenue projections and cost savings, which inflated its EBITDA targets for 2025 [4]. - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible for compensation [1][4]. - A lead plaintiff must file a motion with the court by August 1, 2025, to represent other class members in the litigation [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [3].

Core Viewpoint - A class action lawsuit has been filed against Civitas Resources, Inc. for allegedly misleading investors about its production capabilities and financial condition during the specified class period [1][2]. Allegations - Civitas is accused of failing to disclose significant reductions in oil production expected in 2025 due to declines after a production peak in Q4 2024 and a low TIL count at the end of 2024 [2]. - The company would need to acquire additional acreage and development locations to increase oil production, which would incur significant debt and potentially require selling corporate assets [2]. - Financial conditions would necessitate disruptive cost-reduction measures, including a significant workforce reduction [2]. - The company's business and financial prospects, as well as operational capabilities, were allegedly overstated [2]. Stock Price Impact - Following the revelation of these issues on February 24, 2025, Civitas's stock price dropped by $8.95 per share, representing a decline of over 18%, closing at $40.35 per share on February 25, 2025 [2]. Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by July 1, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3]. Company Background - Civitas Resources, Inc. is an independent exploration and production company focused on crude oil and liquids-rich natural gas in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico [1].

Group 1 - A class action has been filed on behalf of investors who purchased PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024, and March 3, 2025 [1] - PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with its lead product candidate being PGN-EDO51 for Duchenne muscular dystrophy (DMD) [1] - Allegations against PepGen include misleading investors about the effectiveness and safety of PGN-EDO51, deficiencies in the CONNECT2 study, and overstated clinical and commercial prospects [2] Group 2 - On January 29, 2025, PepGen reported safety concerns in the CONNECT1 study and FDA concerns regarding the CONNECT2 study, leading to a stock price drop of $0.40 per share (21.74%) [3] - Following a press release on March 4, 2025, announcing a voluntary pause of the CONNECT2 study, PepGen's stock price fell by $0.53 per share (18.86%) [4] - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025 [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against DoubleVerify Holdings, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against DoubleVerify - The complaint alleges that DoubleVerify misled investors by failing to disclose that customers were shifting ad spending to closed platforms, where the company's capabilities were limited [5]. - It is claimed that the monetization of DoubleVerify's high-margin Activation Services was hindered by the expensive and time-consuming development of technology for closed platforms [5]. - The complaint states that DoubleVerify's competitors were better positioned to incorporate AI into their offerings, negatively impacting the company's competitive edge and profits [5]. - Allegations include systematic overbilling of customers for ad impressions served to declared bots, which undermined the integrity of DoubleVerify's services [5]. - The company's risk disclosures were characterized as materially false and misleading, presenting adverse facts as mere possibilities [5]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through disclosures in February and March 2025, leading to a significant stock price drop of 36% following disappointing earnings and the suspension of services by a major customer [6]. - A report from Adalytics Research in March 2025 claimed that DoubleVerify's services were ineffective, further damaging investor confidence [6]. Group 3: Legal Proceedings - The lead plaintiff in the class action lawsuit will be the investor with the largest financial interest who is also typical of class members, overseeing the litigation on behalf of the class [7]. - Any member of the putative class can move to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [7].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Fortrea To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Fortrea between July 3, 2023 and February 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Red Cat Holdings, Inc. for alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by July 21, 2025 [3][5]. Group 1: Allegations Against Red Cat - The complaint alleges that Red Cat and its executives made false and misleading statements regarding the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract [5][8]. - Defendants claimed that the SRR Contract could generate hundreds of millions to over a billion dollars in revenues, which was later contradicted by actual production capabilities [7][13]. - Following disclosures about the facility's actual production capacity being only 100 drones per month, Red Cat's stock price fell by 8.93% [10]. Group 2: Financial Performance and Stock Impact - In Q1 of fiscal year 2025, Red Cat reported losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing estimates by $1.07 million [11]. - After announcing a pause in manufacturing due to retooling, Red Cat's stock price dropped by 25.32% over two trading sessions [11]. - Following the Kerrisdale Report, which alleged that the SRR Contract was worth only $20 million to $25 million, Red Cat's stock price fell by 21.54% [14]. Group 3: Company Developments - Red Cat was selected by the U.S. Department of Defense for the SRR Program, which aims to provide small, portable drones to Army platoons [6]. - The company announced that it had won the SRR Contract, projecting potential revenues of $50 million to $79.5 million for fiscal year 2025 [12]. - The Salt Lake City Facility's construction was reported as "substantially completed," with a potential future production capacity of 1,000 drones per month, contingent on further investments [9].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of the quarterly dividend payout by over 70% [4]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price drop of more than 27% [5]. Group 2: Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 3: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for securing substantial monetary relief for investors in securities fraud cases [7].